PRISM Rounds: Pulmonary Critical Care & Sleep Podcast
In this episode of PRISM Rounds, we discuss the JAMA 2026 randomized clinical trial by Ornowska and colleagues testing whether 4% tetrasodium EDTA, or t-EDTA, used as a locking fluid for inactive central venous access device lumens, can reduce CVAD-associated complications in adult ICU patients. This pragmatic, triple-blind, multicenter, cluster-randomized crossover trial included 1468 ICU patients across 6 Canadian hospitals. The primary composite outcome—CVAD-associated bloodstream infection, catheter occlusion requiring alteplase, or catheter removal due to occlusion—occurred at 13.1 vs 19.9 events per 1000 catheter-days with t-EDTA versus control. The main signal was fewer catheter occlusions requiring alteplase; infection and thrombosis events were uncommon and should not be overinterpreted. Article link: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6025 [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6025?utm_source=chatgpt.com] Tags Critical Care, ICU, Central Line, CVAD, EDTA, t-EDTA, CLABSI, Catheter Occlusion, Alteplase, Venous Thrombosis, Infection Prevention, Vascular Access, JAMA, Randomized Trial, Pulmonary Critical Care, FOAMed, PRISMRounds
44 episoder
Kommentarer
0Vær den første til at kommentere
Tilmeld dig nu og bliv en del af PRISM Rounds: Pulmonary Critical Care & Sleep Podcast-fællesskabet!